ANGPTL3 Inhibitors Market Report Scope and Overview:

The ANGPTL3 Inhibitors Market was valued at USD 0.21 Billion in 2025 and is projected to reach USD 3.48 Billion by 2035, registering a CAGR of 32.4% from 2026 to 2035.

The ANGPTL3 Inhibitors Market is developing rapidly owing to the increase in its pipeline from a first-in-class monoclonal antibody of Regeneron to RNA interference, antisense, and gene editing therapies. The clinical effectiveness of ANGPTL3 inhibition for mixed hyperlipidemia and severe hypertriglyceridemia has been confirmed. In addition, the scope of indication for ANGPTL3 inhibitors has widened. Significant growth is being witnessed in the deployment of subcutaneous RNAi therapeutics offering infrequent dosing, in vivo base-editing platforms designed for one-time permanent treatment, and expanding real-world clinical evidence, considering that pharmaceutical companies, specialty clinics, and hospitals continue investing heavily in next-generation lipid-lowering technology that reaches patients underserved by conventional cholesterol therapies.

Arrowhead Pharmaceuticals, Inc. announced plans to begin a Phase III study of zodasiran in patients with homozygous familial hypercholesterolemia throughout 2025, following positive Phase IIb ARCHES-2 results demonstrating robust and durable reductions in triglycerides and non-HDL cholesterol among patients with mixed hyperlipidemia.

To Get More Information On ANGPTL3 Inhibitors Market - Request Free Sample Report

ANGPTL3 Inhibitors Market Trends

• Rapid pipeline diversification continues beyond monoclonal antibodies into RNAi, antisense, and gene-editing modalities.

• Growing clinical evidence continues supporting ANGPTL3 inhibition across mixed hyperlipidemia and severe hypertriglyceridemia.

• Rising adoption of infrequent-dosing subcutaneous RNAi therapeutics continues improving long-term patient adherence.

• Expanding in vivo base-editing research continues advancing toward potentially one-time, permanent lipid-lowering treatment.

• Increasing real-world evidence generation continues supporting broader payer coverage for ANGPTL3-targeted therapies.

U.S. ANGPTL3 Inhibitors Market Outlook

The U.S. ANGPTL3 Inhibitors Market was valued at approximately USD 0.11 Billion in 2025 and is projected to reach approximately USD 1.64 Billion by 2035, registering a CAGR of approximately 31.0% from 2026 to 2035.

Demand across the United States continued to be shaped by the country's position as the first and largest commercial market for EVKEEZA, a dense concentration of lipid specialty clinics and academic medical centers treating homozygous familial hypercholesterolemia, and the country's leadership in RNAi and gene-editing clinical development. Rising deployment of next-generation pipeline candidates by leading biotechnology companies running late-stage trials continued reinforcing the country's position as both the largest and most clinically advanced ANGPTL3 inhibitor market. Growing adoption across specialty lipid clinics and academic medical centers added further layers of sustained domestic demand well beyond the original ultra-rare disease use case, with expanding mixed hyperlipidemia and severe hypertriglyceridemia indications increasingly relying on next-generation ANGPTL3-targeted therapies.

Verve Therapeutics, Inc. continued advancing its VERV-201 program throughout the year, an investigational in vivo base-editing therapy designed to permanently reduce ANGPTL3 activity, with key clinical program updates anticipated for patients with refractory hypercholesterolemia and homozygous familial hypercholesterolemia.

ANGPTL3 Inhibitors Market Segment Analysis

• By Drug Class, Monoclonal Antibodies segment dominated the ANGPTL3 Inhibitors Market in 2025 with 71% share; RNA Interference (RNAi) Therapeutics segment is the fastest growing segment.

• By Indication, Homozygous Familial Hypercholesterolemia (HoFH) segment dominated the market in 2025 with 64% share; Mixed Hyperlipidemia segment is the fastest growing segment.

• By Route of Administration, Intravenous segment dominated the market in 2025 with 68% share; Subcutaneous segment is the fastest growing segment.

• By End-User, Hospitals segment dominated the market in 2025 with 62% share; Specialty Clinics segment is the fastest growing segment.

By Drug Class: Monoclonal Antibodies Lead, RNAi Therapeutics Emerge as Fastest-Growing Segment

Monoclonal Antibodies was the leading product segment of the ANGPTL3 Inhibitors Market in 2025, owing to the fact that the drug EVKEEZA was the sole FDA-approved ANGPTL3 inhibitor and had been in commercial sales for years ahead of all competitors in clinical trials. Reimbursement channels, clinical data generated in the real world, and experience of lipidologists in using monoclonal antibodies kept this therapy as the standard of care for the treatment of known cases of homozygous familial hypercholesterolemia patients.

The RNA Interference (RNAi) Therapeutics segment is the fastest growing in the ANGPTL3 Inhibitors Market owing to Arrowhead Pharmaceuticals' rapid advancement of zodasiran into Phase III development, offering infrequent subcutaneous dosing that could substantially improve convenience over intravenous monoclonal antibody infusion. Growing clinical evidence supporting RNAi-mediated ANGPTL3 knockdown across broader hyperlipidemia indications beyond the ultra-rare HoFH population continues expanding this modality's addressable patient base. Rising competitive investment from RNAi platform leaders is accelerating clinical development timelines across this rapidly maturing therapeutic modality.

By Indication: HoFH Dominates, Mixed Hyperlipidemia Gains Fastest Momentum

The Homozygous Familial Hypercholesterolemia (HoFH) segment dominated the ANGPTL3 Inhibitors Market because it represents the only indication with an approved therapy, EVKEEZA, and the primary regulatory pathway that every pipeline candidate has pursued first given the ultra-rare disease's clear unmet medical need. Strong orphan drug incentives, accelerated regulatory pathways, and extensive genetic testing infrastructure for HoFH diagnosis sustained this indication's dominant position throughout the base year. Continued expansion of newborn and cascade genetic screening programs reinforced the diagnosed HoFH patient population driving segment revenue.

The Mixed Hyperlipidemia segment is the fastest growing as Arrowhead's positive Phase IIb ARCHES-2 results demonstrated that ANGPTL3 inhibition could address a substantially larger patient population beyond the ultra-rare HoFH indication. Rising clinical evidence supporting robust and durable triglyceride and non-HDL cholesterol reductions in this broader dyslipidemia population continues expanding the addressable market well beyond genetic cholesterol disorders. Growing pharmaceutical investment in mixed hyperlipidemia clinical trials is driving faster indication expansion across this substantially larger patient population.

By Route of Administration: Intravenous Dominates, Subcutaneous Grows Fastest

The Intravenous segment dominated the ANGPTL3 Inhibitors Market because EVKEEZA, the only approved ANGPTL3 inhibitor, is administered as an intravenous infusion at specialty infusion centers and hospitals. Established infusion center infrastructure and clinician familiarity with monoclonal antibody administration protocols sustained intravenous delivery as the default route throughout the base year. Continued reliance on hospital and specialty infusion settings for HoFH patient management reinforced this route's dominant contribution to total market revenue.

The Subcutaneous segment is expected to witness the fastest growth in the ANGPTL3 Inhibitors Market as RNAi and antisense candidates in development, including zodasiran, are designed for infrequent subcutaneous self-administration or brief clinic visits rather than lengthy infusion appointments. Growing patient and physician preference for less burdensome dosing schedules continues driving pharmaceutical companies to prioritize subcutaneous formulation development. Expanding subcutaneous pipeline candidates approaching late-stage trials continue attracting a broadening base of patients seeking more convenient treatment options.

Regional Analysis

North America ANGPTL3 Inhibitors Market Insights

North America led the ANGPTL3 Inhibitors Market with the largest share of 58.0% in 2025. The region's position as the first and largest commercial market for EVKEEZA, a dense concentration of lipid specialty clinics, and the country's leadership in RNAi and gene-editing clinical development continued reinforcing this dominant regional position. A deep concentration of leading biotechnology companies, academic medical centers, and lipid disorder research programs headquartered across the continent gave regional patients early access to next-generation ANGPTL3-targeted therapies well ahead of most other regions.

The United States accounted for roughly 92.00% of regional revenue, anchored by EVKEEZA's established commercial infrastructure, rapid clinical-stage pipeline advancement from Arrowhead, Verve, and other biotechnology leaders, and extensive genetic testing and lipid specialty clinic networks. Canada added further regional demand through its own growing lipid disorder treatment infrastructure and expanding public health system interest in advanced cholesterol therapies, and that combined strength kept the continent the largest addressable market for ANGPTL3 inhibitor developers through the forecast period.

Get Customized Report as Per Your Business Requirement - Enquiry Now

Europe ANGPTL3 Inhibitors Market Insights

Europe held a meaningful share of global revenue, supported by rising diagnosed prevalence of homozygous familial hypercholesterolemia, expanding national reimbursement discussions for ANGPTL3-targeted therapies, and continued growth of specialty lipid disorder treatment programs across the region's major economies. Regulatory harmonization under the European Medicines Agency and continued expansion of genetic testing infrastructure continued lowering historically significant barriers to advanced ANGPTL3 inhibitor technology adoption across the continent.

Germany led demand at roughly 21.20% of European revenue, supported by its substantial specialty lipid clinic infrastructure and high per-capita genetic cholesterol disorder diagnosis rates among the region's largest economies. The UK and France contributed substantial additional demand through their own expanding lipid disorder treatment programs, and continued European regulatory and reimbursement progress should keep regional demand for ANGPTL3 inhibitor therapeutics climbing through the forecast period.

Asia Pacific ANGPTL3 Inhibitors Market Insights

Asia Pacific is expected to grow at the fastest CAGR of about 38.0% from 2026 to 2035, driven by rising diagnosed prevalence of genetic lipid disorders, expanding clinical trial infrastructure, and growing government-backed investment in advanced cardiometabolic care across the region's largest economies. That combination of an expanding diagnosed patient population and growing regional clinical trial participation kept the region's growth trajectory well ahead of every other region tracked in this report.

Japan led the pack, supported by its sophisticated rare-disease regulatory pathways and strong genetic cholesterol disorder screening infrastructure. China and South Korea contributed meaningful additional demand, with China's rapidly expanding clinical trial capacity and South Korea's advanced specialty lipid clinic infrastructure both reinforcing the region's position as the fastest-growing market tracked in this report.

MEA and Latin America ANGPTL3 Inhibitors Market Insights

The Middle East and Africa and Latin America both showed steady growth, driven by expanding genetic testing infrastructure, rising government investment in tertiary cardiometabolic care, and growing clinician awareness of ANGPTL3-targeted treatment options across both areas. As these markets continued building out modern lipid disorder management infrastructure, ANGPTL3 inhibitors proved a genuinely valuable option for a small but clinically underserved population of genetic cholesterol disorder patients.

Saudi Arabia led Middle East and Africa demand on account of its substantial spending in healthcare amid the efforts towards transformation of the country and owing to the higher incidence of HoFH caused by consanguinity. The UAE also contributed to the generation of demand through its burgeoning healthcare specialization. In Latin America, Brazil accounted for the largest share of regional revenue, with growing genetic testing adoption and specialty lipid clinic development continuing to anchor regional demand for ANGPTL3 inhibitor therapeutics.

Market Dynamics

Growth Drivers: Rising Genetic Lipid Disorder Diagnosis and Pipeline Diversification

The industry is driven by rising diagnosed prevalence of homozygous familial hypercholesterolemia and other genetic lipid disorders, growing pipeline diversification beyond monoclonal antibodies into RNAi, antisense, and gene-editing modalities, increasing clinical evidence supporting ANGPTL3 inhibition across broader hyperlipidemia indications, and expanding genetic testing infrastructure improving patient identification. As physician awareness of ANGPTL3's LDL receptor-independent mechanism continues rising, the need for effective treatment options for patients unresponsive to conventional cholesterol therapy continues driving adoption of ANGPTL3-targeted therapeutics.

Rising clinical evidence supporting ANGPTL3 inhibition beyond the ultra-rare HoFH indication continues reinforcing this driver, as positive mixed hyperlipidemia trial results open a substantially larger addressable patient population than the original approved indication. Growing competitive investment from RNAi, antisense, and gene-editing platform leaders continues expanding the diversity of modalities available for evaluation, and that combination of clinical validation and modality diversification is exactly what keeps demand climbing at such an extraordinary, sustained pace.

Restraints: High Treatment Costs and Ultra-Rare Disease Diagnosis Gaps

The substantial cost of ANGPTL3-targeted therapies continues posing a genuine restraint on faster market-wide expansion, particularly across emerging healthcare systems and smaller specialty clinics without the reimbursement infrastructure needed to support broad patient access to premium genetic lipid disorder treatment. That cost profile has kept large-scale ANGPTL3 inhibitor treatment access concentrated among a comparatively small number of well-resourced specialty lipid centers.

Persistent underdiagnosis of homozygous familial hypercholesterolemia and other genetic lipid disorders continues posing a further restraint, as many patients with severe genetic dyslipidemia remain unidentified due to limited genetic testing infrastructure and cascade screening programs in many healthcare systems. That diagnosis gap keeps a substantial portion of the eligible patient population outside the reach of currently available and pipeline ANGPTL3-targeted therapies.

Opportunities: Indication Expansion and Gene-Editing Innovation

Rising investment in mixed hyperlipidemia and severe hypertriglyceridemia indications represents a genuinely significant opportunity, as pipeline candidates increasingly demonstrate efficacy across patient populations far larger than the original ultra-rare HoFH approval. Companies positioned early in broader hyperlipidemia indication development stand to capture meaningful share as this therapeutic class continues expanding from a narrow orphan-disease niche into mainstream cardiometabolic treatment.

Advancing in vivo gene-editing platforms offers a second substantial opportunity, as one-time, potentially permanent ANGPTL3 reduction could fundamentally differentiate treatment economics compared with chronic, repeated-dosing therapies. Companies with proven, scalable gene-editing and RNAi delivery platforms stand to capture meaningful share as the therapeutic class matures from its current single-approved-product state into a genuinely diversified, multi-modality competitive market over the coming decade.

Recent Developments:

• 2025: Arrowhead Pharmaceuticals, Inc. announced plans to begin a Phase III study of zodasiran in patients with homozygous familial hypercholesterolemia, following positive Phase IIb ARCHES-2 results in mixed hyperlipidemia.

• 2024: Arrowhead Pharmaceuticals, Inc. reported Phase IIb ARCHES-2 study results showing zodasiran achieved robust and durable reductions in triglycerides, triglyceride-rich lipoprotein remnants, and non-HDL cholesterol in mixed hyperlipidemia.

• 2025: Verve Therapeutics, Inc. announced plans to report key program updates for VERV-201, its investigational in vivo base-editing therapy targeting ANGPTL3, in patients with refractory hypercholesterolemia and homozygous familial hypercholesterolemia.

• 2025: Regeneron Pharmaceuticals, Inc. continued expanding real-world clinical evidence supporting EVKEEZA (evinacumab-dgnb), the first and only FDA-approved ANGPTL3 inhibitor, since its original 2021 approval for homozygous familial hypercholesterolemia.

• 2025: Ionis Pharmaceuticals, Inc. continued advancing next-generation ligand-conjugated antisense candidates targeting ANGPTL3 through its LICA platform, building on earlier clinical experience from its discontinued vupanorsen program.

ANGPTL3 Inhibitors Market key players are:

• Regeneron Pharmaceuticals, Inc.

• Arrowhead Pharmaceuticals, Inc.

• Verve Therapeutics, Inc.

• Ionis Pharmaceuticals, Inc.

• Silence Therapeutics plc

• Eli Lilly and Company

• Novartis AG

• Amgen Inc.

• Alnylam Pharmaceuticals, Inc.

• Beam Therapeutics Inc.

• Intellia Therapeutics, Inc.

• Esperion Therapeutics, Inc.

• Merck & Co., Inc.

• AstraZeneca plc

• Bristol-Myers Squibb Company

• Daiichi Sankyo Company, Limited

• Sanofi S.A.

• Novo Nordisk A/S

• GlaxoSmithKline plc

• Takeda Pharmaceutical Company Limited

ANGPTL3 Inhibitors Market Report Scope: